• Health Care Bulletin

    Behind the Headlines in Pharmaceutical Investigations

    Press attention has been trained on government investigations of pharmaceutical firms’ marketing practices in China, India, Eastern Europe, and elsewhere. Managing Principal Paul Greenberg describes how economists can play an important role in these cases.

    Behind the Headlines in Pharmaceutical Investigations
  • AG Feature

    Using Epidemiology to Identify Unmet Need

    When a new renal cell carcinoma treatment faced global reimbursement challenges – because an available on-market drug was considered “standard of care” – Analysis Group undertook an international epidemiological study of patients receiving the existing therapy.

  • Health Care Bulletin

    Using Canadian Provincial Health Plan Claims

    Analysis Group researchers used data from Québec, Canada’s provincial health plan to assess the prevalence of combining or switching ADHD therapies, as well as to evaluate the impact of generic substitution on epilepsy patients.

    Using Canadian Provincial Health Plan Claims
  • AG Feature

    Evaluating International Marketing Access

    Across international pharmaceutical markets, the criteria used to assess the value of new therapies in relation to standards of care vary markedly and are changing rapidly. Read about how manufacturers can determine national and regional payer responses to new therapies, and hear from Vice President Christian Frois on how market access and pricing decisions can drive success in emerging markets.

  • Health Care Bulletin

    Global Consequences of Local Pricing Decisions

    Governments seeking to contain public spending on drugs often set reimbursement based on benchmark countries. Read about how this practice – called reference pricing – can impact global market dynamics.

    Global Consequences of Local Pricing Decisions

Also in this Issuee

Read the Full Issue

Health Care Bulletin: Fall 2013 - Analysis Group